AMARIN SP ADR (AMRN)
$0.40
0.0025 (0.62%)
AMRN Stock Quote Delayed 30 Minutes
All Bets Are Off for Amarin Stock
Much of the upside from flagship drug Vascepa is already priced into Amarin stock. Wait for a pullback before buying AMRN stock.
Previous Close
$0.42
Market Cap
166.75M
PE Ratio
-2.00
EPS
-0.2
Volume (Avg. Vol.)
2.56M
Day's Range
$0.39 - $0.42
52-Week Range
$0.35 - $1.11
Dividend & Yield
N/A (N/A)
AMRN Stock Predictions, Articles, and AMARIN SP ADR News
Amarin Risks Getting Exposed as a Paper Tiger
Pharmaceutical companies are always difficult investment propositions, and Amarin shares proved why with its perhaps unjustifiably hyped drug Vascepa.
Vascepa’s Future Looks Rosy, But It Could Still Be Fishy for Amarin Stock
Amarin is doubling its sales force for Vascepa, a cholesterol-fighting drug, as potential competitors await results from their own trials.
Health for Patients, Wealth for Investors: Watch Amarin Stock Closely
On the heels of a long-awaited FDA approval, Amarin stock is just what the doctor ordered. Here's what you can expect from AMRN in 2020.
Here’s Why Amarin Stock Slumped Despite the FDA Approval
Although the FDA approval is nice, fundamentally, Amarin stock is banking on a fish oil drug. Given its similarity to OTC counterparts, that doesn’t bode well for stakeholders.
Amarin Stock Will Keep Powering Higher In 2020
The days of 50%-plus annual gains for Amarin stock are over, but that doesn't mean it's done moving higher. Here's why it should keep climbing in 2020.
The Success of Vascepa Actually Might Be a Problem for Amarin
Amarin is expecting an increase in sales for its fish-oil derived drug Vascepa. But investors are questioning if Amarin may be an M&A target.
Taking Amarin Profits Is Probably a Good Idea Right Now
Last week's slide very could be a sign that plenty of investors are already dumping Amarin following the Food and Drug Administration's (FDA) approval of the Vascepa drug, a fish oil-based treatment used to reduce a patient's chance of falling victim to major cardiovascular issues, such as heart attacks and strokes.
Amarin Stock is at Sky-High Levels Already Assumes All the Good News
Amarin stock is at sky high levels assuming all the good news. The FDA drug approval was anticipated and the AMRN stock price had implied it already.
Why Longer-Term Investors Should Buy Amarin Stock on Weakness
Short sellers have targeted AMRN and the Amarin stock price is quite undervalued, making the shares quite attractive for long-term investors.
Amarin’s Vascepa Approval Seems Fishy for Patients and AMRN Investors
What does the FDA's recent approval of Vascepa mean for Amarin stock? Is the company really a target for buyout offers?
Amarin Has the Makings for a Gamechanging Product
Amarin is targeting a huge market, and its main drug -- Vascepa -- is likely to be expanded in its coverage. Here’s a look at what’s ahead for the stock.
Amarin Stock Has Lower Risk, But How Much Reward?
An FDA approval unquestionably is good news for Amarin. But valuation remains a concern.
For Now, Amarin Stock Is a Gamble on FDA Approval
Although Amarin stock could potentially skyrocket off the pharmaceutical’s flagship drug Vascepa, approval challenges make this play incredibly risky.
Amarin Stock’s Big Q4 Gains May Not Last as Big Dogs are Barking
Thanks to the effective cardiovascular drug Vascepa, Amarin stock has enjoyed an outsized performance so far this year. However, over the horizon stands big pharmaceutical competitors that are ready to spoil the party.
Why the Rally in Amarin Stock Should Hold Strong
Amarin's Vascepa drug should be approved for expanded use soon. This should boost Amarin stock, which makes AMRN a solid buy right now.
The Question is Not Why Amarin Stock May Go Up, But Should It?
Amarin stock is set to move higher on a potential label expansion. But does this mean that the drug will perform well in the market?
5 Top Stock Trades for Wednesday: SPY, DIS, PYPL
PayPal, Disney, Amarin, Overstock and the S&P 500 ETF were our top stock trades for Wednesday. Here's a look at the charts now.
This Biopharmaceutical Stock Looks Like a Steal
This morning, I'm recommending a bullish call option on Amarin Corporation plc (NASDAQ:AMRN), the biopharmaceutical company.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
